FiercePharma

Pharma’s go-to destination for news & trends shaping approved drugs. Delivering news, revealing insights straight to your inbox.

[FiercePharma @FiercePharma]

Insulet, Calm join forces for diabetes care offerings with ‘Mind in Range’ wellness tools https://t.co/32NHMumXIS

[FiercePharma @FiercePharma]

Nearly a decade after spinning out its Chinese research hub to form Dizal Pharmaceutical, AstraZeneca is paying up to $1.5 billion to buy a piece of the pipeline, securing exclusive global rights for the biotech’s oral EGFR lung cancer drug Zegfrovy. https://t.co/0NuX50hl9B

[FierceBiotech @FierceBiotech]

A new Fierce Biotech special report examines the forces shaping emerging biotech hubs. https://t.co/ZzA6AS8M03

[FiercePharma @FiercePharma]

🎧 New today on The Top Line: A $10B deal, China trial scrutiny and highlights from ADA 2026 https://t.co/kdFreAyqQZ

[FiercePharma @FiercePharma]

While AstraZeneca and Ionis’ shock miss in ATTR-CM sent the companies’ shares tumbling, one analyst thinks investors may have overreacted
https://t.co/aUhbEUKhz5

[FiercePharma @FiercePharma]

Vera’s new FDA nod portends an IgAN showdown with a pair of pharma heavyweights
https://t.co/92IopFM34a

[FiercePharma @FiercePharma]

The narrative is shifting around the U.S. biosimilar market, with big opportunities ahead for developers who play their cards right
https://t.co/T4ATIosKCS

[FiercePharma @FiercePharma]

BridgeBio has secured $1B to support new launches, but at least one analyst thinks the company could be entertaining other plans
https://t.co/mtFG0nomeo

[FiercePharma @FiercePharma]

Orca Bio makes a splash with FDA approval for cell therapy Tregzi. Could an IPO come next? https://t.co/aGASHBxyki

[FiercePharma @FiercePharma]

Consumer health giant Haleon has tapped Microsoft to incorporate AI across its operations https://t.co/O8FT56F9hK

[FiercePharma @FiercePharma]

Kimball lays out $103M to bolster life sciences CDMO footprint across Europe, India https://t.co/HshIDLQf3c

[FiercePharma @FiercePharma]

Medical journal retracts Tavneos pivotal study article, complicating Amgen’s defense effort https://t.co/UzSElwEjpf

[FierceBiotech @FierceBiotech]

FDA gene therapy regulator Vijay Kumar steps down from leadership role https://t.co/AgZLSwkjji

[FiercePharma @FiercePharma]

Klick Health has struck its third takeover in 18 months, snapping up Oxford PharmaGenesis to expand its global reach and deepen its scientific expertise. https://t.co/MOqv5PWTMj

[FiercePharma @FiercePharma]

BeOne’s Brukinsa hits goal in mantle cell lymphoma confirmatory trial https://t.co/1foFBqEpeW

[FiercePharma @FiercePharma]

Unicycive turned away by FDA again over manufacturer’s plant shortfalls https://t.co/M8VT04ual6

[FiercePharma @FiercePharma]

Despite a recent failure as a second-line monotherapy in diffuse B-cell lymphoma, a positive phase 3 combination trial for AbbVie and Genmab’s Epkinly has renewed confidence ahead of its high-stakes first-line readout. https://t.co/VciBXMqEZZ

[FiercePharma @FiercePharma]

FDA selects Lilly, Regeneron, Fujifilm, 4 others for PreCheck Pilot Program https://t.co/bKjZDXQ4sR

[FiercePharma @FiercePharma]

Viridian has secured an FDA nod for Lumvoa to treat the eye-bulging condition TED, triggering competition with Amgen’s blockbuster Tepezza. https://t.co/Flb36lrRNB

[FiercePharma @FiercePharma]

Nature Medicine has pulled a controversial paper tying lung cancer survival to PD-1 treatment timing
https://t.co/JxAbOc6gI8